ArticleJournal of diabetes research2018
DPP-4 Inhibitor Sitagliptin Improves Cardiac Function and Glucose Homeostasis and Ameliorates
Article in Journal of diabetes research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- Long-term and short-term exposure to outdoor air pollution and its association with glycolipid metabolic disorders.World journal of diabetes · 2025Article
- Quinoa Ameliorates High-Fat Diet-Induced Obesity in Female Mice by Regulating Gut Microbiota and Adipogenesis.Food science & nutrition · 2025Article
- A novel combination of sitagliptin and melatonin ameliorates T2D manifestations: studies on experimental diabetic models.Journal of endocrinological investigation · 2023Article
- LRP6 Bidirectionally Regulates Insulin Sensitivity through Insulin Receptor and S6K Signaling in Rats with CG-IUGR.Current medical science · 2023Article
- Cardiovascular protection by DPP-4 inhibitors in preclinical studies: an updated review of molecular mechanisms.Naunyn-Schmiedeberg's archives of pharmacology · 2022Review
- Common Genetic Aberrations Associated with Metabolic Interferences in Human Type-2 Diabetes and Acute Myeloid Leukemia: A Bioinformatics Approach.International journal of molecular sciences · 2021Article
- DPP-4 inhibition resembles exercise in preventing type 2 diabetes development by inhibiting hepatic protein kinase CThe Journal of international medical research · 2020Article
- Association of glycemic variability with left ventricular diastolic function in type 2 diabetes mellitus.Cardiovascular diabetology · 2019Article
- Alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function in diabetic rabbits.Cardiovascular diabetology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic overnutrition leads to cardiac dysfunction and insulin (INS) resistance. Dipeptidyl peptidase-4 (DPP-4) improves glucose metabolism and insulin sensitivity in both human and animal models. In this study, we explored whether DPP-4 inhibitor sitagliptin (SIT) is involved in the protection of cardiac function and
methodsSix-week-old C57BL6/J mice were fed a high fat and fructose Western diet with DPP-4 inhibitor SIT for 12 weeks. Cardiac function was examined by echocardiography. Body weight, plasma glucose, and insulin concentrations were measured. The contents of total S6 kinase 1 (S6K1), phosphorylation of S6K1 activation, and INS docking proteins INS receptor substrates 1 and 2 (IRS-1, IRS-2) were assayed, and histology of heart tissue was performed.
resultsChronic Western diet consumption elevated plasma glucose and insulin and caused obesity, diastolic dysfunction, and
conclusionsThis study revealed pleiotropic protective effects of DPP-4 inhibitor SIT on cardiac function, glycemia, and
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.